Arcellx acquired by Gilead Sciences

Obagi Medical, a medical-grade skincare company positioned in the professional dermatology and aesthetics segment, is being acquired by Bridgepoint as part of a broader consolidation trend across clinical skincare markets. The transaction reflects a strategy focused on building specialised platforms within dermatology and aesthetics, supported by structural growth driven by the medicalisation of skincare routines and the convergence of beauty and healthcare. Bridgepoint aims to build an integrated platform of clinical skincare and aesthetics brands covering a broader spectrum of solutions, from dermatological treatments to injectable aesthetic products

Stryker has completed the acquisition of Amplitude Vascular Systems, a private medical device company, which develops a next-generation intravascular lithotripsy (IVL) platform, designed to treat complex peripheral arterial disease, this acquisition represents a significant milestone in the expansion of Stryker's peripheral vascular portfolio, by integrating Amplitude Vascular Systems' innovative technology, which uses carbon dioxide-generated pressure waves, to optimize arterial diameter, while minimizing damage and improving deliverability, treatment speed, and therapeutic efficacy, with the goal of strengthening Stryker's position in peripheral vascular solutions, by offering solutions for physicians and patients, to treat cardiovascular disease, Stryker's strategy is to develop its portfolio of products and services, to improve patient and healthcare outcomes, by offering innovative and integrated solutions, for physicians, hospitals, and patients, financial and legal advisory services were provided by reputable consulting firms, to ensure the success of the operation

The group has finalized a binding agreement to acquire the total share capital of the target from Alfasigma S.p.A., a maneuver designed to fundamentally expand its specialized manufacturing capabilities. The strategic rationale for this transaction centers on a "technology-integration" play, merging the target's industry-leading expertise in liquid and semi-solid pharmaceuticals with the group’s established global leadership in the CSDMO sector. This fusion effectively creates a specialized powerhouse in the contract manufacturing arena, providing the organization with the technical operational depth required to address the increasing demand for diverse dosage forms

The group has finalized a definitive agreement to acquire the entire share capital of the target, a maneuver designed to fundamentally expand its presence as a turnkey provider in the global eye care market. The strategic rationale for this transaction centers on a "portfolio-convergence" play, merging the target's industry-leading technical operational depth in refraction and finishing with the group’s established leadership in tonometry and imaging. This fusion effectively creates a specialized powerhouse in the ophthalmic arena, providing the organization with the scientific talent and technological hardware required to address the increasing complexity of diagnostic and optical retail workflows

UCB has entered into a definitive agreement to acquire Neurona Therapeutics, a maneuver designed to fundamentally reinforce the group’s leadership in the global epilepsy market. The strategic rationale for this transaction centers on a "regeneration-acceleration" play, merging the target's industry-leading stem cell platform with the group’s extensive therapeutic expertise and global commercial infrastructure. This fusion effectively creates a specialized powerhouse in the advanced therapies arena, providing the organization with the scientific talent and lead investigational asset required to address the increasing demand for cures in drug-resistant mesial temporal lobe epilepsy

In a structured minority growth equity transaction, specialized family capital investment firm For Talents has acquired a minority stake in Neftys Pharma. This strategic operation is executed alongside incumbent financial sponsors UI Investissement and GENEO Capital Entrepreneur, who are rolling over their investments after an initial four-year holding period. The transaction is fundamentally designed to facilitate the intergenerational transmission of the family-owned enterprise from founder Jacques Mignot to his son, Diego Mignot, who officially assumes the presidency

Vitrex Medical Group (VMG) has finalized the acquisition of a majority stake in Herniamesh, an operation designed to fundamentally accelerate the group's transformation into a global leader in surgical technology. The strategic rationale for this transaction centers on a "portfolio-synergy" play, merging the target's industry-leading technical operational depth in surgical meshes with the group’s extensive distribution network and established suture division (CHIRMAX). This fusion effectively creates a specialized powerhouse in the European medtech arena, providing the organization with the scientific talent and technological hardware required to address the increasing complexity of soft tissue repair and urogynecological procedures

American Industrial Partners has finalized a definitive agreement to acquire Avanos Medical in an all-cash transaction, a maneuver designed to fundamentally reinforce the target's competitive positioning in the specialized medical technology arena. The strategic rationale for this transaction centers on an "operational-transformation" play, merging the target's industry-leading technical operational depth in nutrition and pain therapies with the acquirer's extensive history of implementing transformative operating agendas

Halma, a global leader in healthcare technology, has completed the acquisition of 100% of Surgistar’s share capital, further strengthening its ophthalmic instrument capabilities within its Healthcare division. Through this transaction, Halma aims to bring the production of high-precision disposables in-house, helping to better secure its supply chain against external volatility. From an industrial standpoint, the deal is driven by the combination of Surgistar’s automated sharpening technologies with Halma’s clinical and commercial reach, ensuring consistently high-quality cutting performance for demanding ophthalmic teams

Rantum Private Equity Fund II has successfully finalized the acquisition of a majority stake in the share capital of the target, marking its seventh investment from the current fund. This strategic transaction represents a pivotal step in the acquirer’s objective to establish a dominant position in the high-precision medical technology sector, specifically targeting the resilient demand for minimally invasive surgery. The strategic rationale for the move centers on the high degree of alignment between the target’s fully integrated German manufacturing capabilities and the acquirer’s focus on high-moat, regulatory-intensive industrial platforms